Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 902-906

  Scheithauer, Werner ^a   Kornek, Gabriela V ^a   Raderer, Markus ^a   Valencak, Julia ^a   Weinländer, Georg ^a   Hejna, Michael ^a   Haider, Karin ^a   Kwasny, Werner ^a   Depisch, Dieter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPHIL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; VOMITING;

EID: 0033047747     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.902     Document Type: Article

References (19)

1. Bertino JR: Chemotherapy of colorectal cancer: History and new themes. Semin Oncol 24:518-3-518-7, 1997 (suppl 18)
2. Herrmann R: 5-Fluorouracil in colorectal cancer: A never ending story. Ann Oncol 7:551-552, 1996
3. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
4. Clark JW: Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol 24:518-19-518-24, 1997 (suppl 18)
5. Harstrick A, Vanhoefer U, Seeber S: New drugs in colorectal cancer: A review of antitumor activity and cross-resistance patterns of topoisomerase I inhibitors, thymidylate synthetase inhibitors, and oxaliplatin. Onkologie 21:95-103, 1998
6. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
7. Ducreux M, Louvet C, Bekradda M, et al: Oxaliplatin for the treatment of advanced colorectal cancer: Future directions. Semin Oncol 25:47-53, 1998 (suppl 5)
8. Zeghari-Squalli N, Misset JL, Cvitkovic E, et al: Mechanism of the in vitro synergism between SN38 and oxaliplatin. Proc Am Assoc Cancer Res 38:A20, 1997 (abstr)
9. Cvitkovic E, Wasserman E, Goldwasser F, et al: Preliminary report on an oxaliplatin (LOHP)/CPT-11 phase I trial in gastrointestinal (GI) malignancies: An active combination. Proc Am Soc Clin Oncol 16:229, 1997 (abstr)
10. Goldwasser F, Chouaki N, Buthaud X, et al: CPT-11/oxaliplatin (L-OHP) every two weeks: A phase I study in patients (pts) with advanced digestive tumors. Proc Am Soc Clin Oncol 17:927A, 1998 (abstr)
11. Ribas A, Albanell J, Bellmunt J, et al: Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 14:1573-1580, 1996
12. World Health Organization: Handbook for reporting results of cancer treatment [WHO Offset Publication No. 48]. Geneva, Switzerland, World Health Organization, 1979
13. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13:346-353, 1961
14. Anderson JR, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quartiles in life-table analysis. Biometrics 38:407-416, 1982
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:458-481, 1958
16. Bleiberg H, De Gramont A: Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32-39, 1998 (suppl 5)
17. Schmoll HJ, Büchele T, Schöber C: The role of second-line chemotherapy in colorectal cancer. Onkologie 20:288-294, 1997
18. Van Cutsem E, Bajetta E, Niederle N, et al: A phase III multicenter randomized trial comparing CPT-11 to infusional 5FU regimen in patients (pts) with advanced colorectal cancer (ACRC) after 5FU failure. Proc Am Soc Clin Oncol 17:256, 1998 (abstr)
19. Pilot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997